Transkaryotic Therapies TKTX
-
New Morningstar Analyst Report - Shire PLC
… marketing in 2008 of Dynepo (from Transkaryotic Therapies ) after lackluster sales, and ..... years through 2011, including the Transkaryotic Therapies acquisition in 2005, which established ..... global turn with the acquisition of Transkaryotic Therapies in 2005. This move laid the foundation …
-
When Inflation Fuels Deflation
… to December from September, the uncertainty continues over which drug(s), Genzyme's or that of rival Transkaryotic Therapies , will be approved and when. If Fabrazyme is approved and given orphan drug status (meaning Transkaryotic …
-
New Morningstar Analyst Report - Shire PLC
… marketing in 2008 of Dynepo ( from Transkaryotic Therapies ) after lackluster sales , and ..... years through 2009 , including the Transkaryotic Therapies acquisition in 2005 which established ..... global turn with the acquisition of Transkaryotic Therapies in 2005 . This move laid the foundation …
-
New Morningstar Analyst Report - Shire PLC
… marketing in 2008 of Dynepo (from Transkaryotic Therapies ) after lackluster sales, and ..... years through 2008, including the Transkaryotic Therapies acquisition in 2005 which established ..... global turn with the acquisition of Transkaryotic Therapies in 2005. This move laid the foundation …
-
FDA Approves Shire's Elaprase
… product portfolio. Shire received rights to Elaprase, a human enzyme replacement therapy, when it acquired Transkaryotic Therapies , and we remain impressed by the productivity of this acquisition. Elaprase has orphan drug status, which …
-
Stock Analyst Note - Genzyme
… up from $35 previously, in light of the drugs' approvals. After a bitter, long-fought battle with Transkaryotic Therapies TKTX , Genzyme won the race to get a Fabry's disease treatment to the U.S. market first. Along with the FDA …
-
Genzyme Drug Gets Virtual Monopoly
… Genzyme's drug seven years of competition-free sales. Fabrazyme, which was in a heated battle with Transkaryotic Therapies ' TKTX Replagal, received orphan-drug status, an incentive that gives market exclusivity for therapies that …
-
Genzyme's Drug Takes Lead
… Genzyme's treatment for Fabry's disease. On Tuesday, the committee voted that a competing drug, Transkaryotic Therapies ' TKTX Replagal, did not provide enough evidence that it worked. The two drugs have been in a heated battle to …
-
Replagal News Good for Genzyme
Genzyme GENZ could benefit if Transkaryotic Therapies ' TKTX Replagal continues to show disappointing trial results. The latter company announced Wednesday that its Fabry disease drug didn …
-
Biotech Analysts' Roundtable
… some sense of whether the stock has carried beyond any reasonable level. There are other cases, such as Transkaryotic Therapies TKTX , where you're looking at the potential for a major product and the potential for a high valuation in the …